GSK (LON:GSK) Earns Underweight Rating from JPMorgan Chase & Co.

GSK (LON:GSK)‘s stock had its “underweight” rating restated by equities researchers at JPMorgan Chase & Co. in a research note issued to investors on Wednesday, Marketbeat reports.

Several other research analysts have also recently issued reports on the company. Shore Capital reissued a “buy” rating on shares of GSK in a research note on Wednesday, August 28th. Berenberg Bank decreased their price target on GSK from GBX 1,820 ($23.07) to GBX 1,600 ($20.28) and set a “buy” rating for the company in a research note on Friday, November 29th. Finally, Deutsche Bank Aktiengesellschaft reissued a “buy” rating and issued a GBX 1,850 ($23.45) price target on shares of GSK in a research note on Tuesday, September 3rd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of GBX 1,805.83 ($22.89).

GSK Price Performance

Shares of LON GSK opened at GBX 1,334 ($16.91) on Wednesday. GSK has a 1-year low of GBX 1,282.50 ($16.26) and a 1-year high of GBX 1,823.50 ($23.11). The firm has a market capitalization of £54.43 billion, a PE ratio of 1,182.91, a P/E/G ratio of 1.24 and a beta of 0.31. The business’s fifty day moving average price is GBX 1,411.08 and its two-hundred day moving average price is GBX 1,530.52. The company has a debt-to-equity ratio of 123.04, a current ratio of 0.82 and a quick ratio of 0.73.

Insider Transactions at GSK

In related news, insider Jonathan Symonds acquired 7,150 shares of the business’s stock in a transaction that occurred on Wednesday, October 30th. The shares were acquired at an average cost of GBX 1,394 ($17.67) per share, with a total value of £99,671 ($126,341.74). Also, insider Elizabeth (Liz) McKee Anderson acquired 446 shares of the business’s stock in a transaction that occurred on Monday, September 23rd. The stock was bought at an average cost of GBX 2,051 ($26.00) per share, for a total transaction of £9,147.46 ($11,595.21). Insiders bought 7,604 shares of company stock valued at $10,893,038 in the last three months. Corporate insiders own 1.61% of the company’s stock.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.